Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine

Author： Molina-Vila Miguel A Teixidó Cristina Costa Carlota

ISSN： 1741-0541

Source： Personalized Medicine, Vol.10, Iss.5, 2013-07, pp. : 415-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

New discoveries in lung cancer biology: paving the road of personalized medicine

By Santos Edgardo S

Therapy, Vol. 8, Iss. 1, 2011-01 ,pp. : 1-4

Future Medicine

Access to resources Recommend Favorite

Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin

By McWilliam Andrew Lutter Randall Nardinelli Clark

Personalized Medicine, Vol. 5, Iss. 3, 2008-05 ,pp. : 279-284

Future Medicine

Access to resources Recommend Favorite

Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk

By Van Bebber Stephanie L Liang Su-Ying Phillips Kathryn A Marshall Deborah Walsh Judith Kulin Nathalie

Personalized Medicine, Vol. 4, Iss. 3, 2007-08 ,pp. : 341-350

Future Medicine

Access to resources Recommend Favorite

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite

Personalized Therapy of Lung Cancer

Oncology Research and Treatment, Vol. 35, Iss. 1, 2012-01 ,pp. : 14-19

Karger

Access to resources Recommend Favorite